Evaxion A/S Sponsored ADR EVAX 深 滬
已收盤 05-08 16:00:00 美东时间
4.34
+0.270
+6.63%
華盛通- 最 高4.50
- 今 開4.01
- 成交量 3.68万股
- 最 低 4.01
- 昨 收 4.07
- 總市值 3619.65万
- 52周最高 12.1499
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.6202
- 委 比 -58.73%
- 總股本 834.02万
- 歷史最高 1252.00
- 量 比 1.44
- 振 幅 12.04%
- 歷史最低 2.871
- 每 手 1
- 風險率 1.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Evaxion Promotes Chief Scientific Officer Birgitte Rono To COO
Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, that Birgitte Rønø, its Chief Scientific Officer (CSO), will take on
04-27 20:05
美股大行评级 | 潜在涨幅33%！大小摩等9家大行上调英特尔目标价；Popular、都福集团、联合太平洋、联合租赁等获多家大行上调评级
今日重点评级关注：瑞银：维持SS&C科技"买入"评级，目标价从112美元升至115美元；Piper Sandler：维持儒博实业"超配"评级，目标价从530美元升至540美元
04-27 14:04
HC Wainwright & Co. Reiterates Buy on Evaxion, Maintains $16 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion (NASDAQ:EVAX) with a Buy and maintains $16 price target.
04-24 18:32
Evaxion Showcases AI-Immunology Platform's Potential To Develop Glioblastoma Vaccines Using Novel Tumor Targets At AACR
Data analysis conducted in collaboration with a leading academic medical center shows that AI‑Immunology™ enables vaccine design also for the deadly brain cancer, glioblastomaUniquely, the platform can identify a
04-18 03:03
Evaxion Announces Final Patient Visit In One-Year Extension Phase 2 Trial Of Personalized Melanoma Cancer Vaccine EVX-01
EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer). In the first two years of the phase 2 trial, patients were treated with EVX-01 in combination with
04-07 20:10
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
HC Wainwright & Co. Reiterates Buy on Evaxion, Maintains $16 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion (NASDAQ:EVAX) with a Buy and maintains $16 price target.
03-09 18:17
Evaxion Earnings Report: Q4 Overview
Evaxion (NASDAQ:EVAX) released its Q4 earnings on Thursday, March 5, 2026 at 09...
03-05 22:38
Evaxion Biotech Q4 EPS $(0.02) Beats $(0.30) Estimate
Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.30) by 93.27 percent. This is a 90.48 percent increase over losses of $(0.21) per share from
03-05 22:35
Insights into Evaxion Q4 Earnings
Evaxion (NASDAQ:EVAX) reported its Q4 earnings results on Thursday, March 5, 20...
03-05 22:32
